# Prolocor

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/prolocor

- Industry: Healthcare
- Headquarters: Philadelphia, US
- Website: www.prolocor.com
- Total disclosed funding: $3.2M
- Latest round: Seed (Aug 16, 2022)
- Investors on record: 2

## About

Founded in 2020 by David Schneider, and Peter M. DiBattiste (CEO), and based in Philadelphia, US, Prolocor Inc. is a healthcare startup that is a diagnostic test developer that uses FcyRIIa platelets to predict an individual's risk of thrombosis. In August 2022, Prolocor Inc. received USD 2 million in grant funding from investor Small Business Innovation Research.

The company provides a precision diagnostic test based on platelet FcRIIa on the surface of platelets, which guides doctors in treatment decisions by matching the intensity of therapy with the risk of events in acute coronary syndrome to prevent thrombosis.

The company intends to use the August 2022 funding to support its FcyRiia diagnostic tool.

## Funding rounds

- Seed, Aug 16, 2022, $3.2M — Green Park & Golf Ventures, LabCorp Ventures

## Investors

- Green Park & Golf Ventures (https://capitalatlas.ai/funds/green-park-golf-ventures) — Seed
- LabCorp Ventures (https://capitalatlas.ai/funds/labcorp-ventures) — Seed